| Code | CSB-RA624104MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to QX002N, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine primarily produced by Th17 cells, γδ T cells, and innate lymphoid cells. IL-17A plays a crucial role in host defense against extracellular pathogens by promoting neutrophil recruitment and activating inflammatory responses. However, dysregulated IL-17A signaling contributes to the pathogenesis of numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Elevated IL-17A levels have also been implicated in certain cancers and chronic inflammatory states.
As a biosimilar to QX002N, this antibody serves as a valuable research tool for investigating IL-17A-mediated inflammatory pathways and immune responses. It enables researchers to explore the therapeutic potential of IL-17A neutralization across various disease models and to elucidate the molecular mechanisms underlying Th17-driven pathology. This antibody supports studies in immunology, inflammation research, and autoimmune disease modeling.
There are currently no reviews for this product.